남아프리카 - 영어 - South African Health Products Regulatory Authority (SAHPRA)

novo nordisk (pty) ltd û (rivonia) - injection - see ingredients - each 1,0 ml solution contains liraglutide 6,0 mg

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

william a cook australia pty ltd - 35094 - catheter guide wire - a stainless steel wire guide with a tapered fixed core. the wire guides are available in a wide variety of lengths, shapes and diameters in order to access various locations within the body. intended to facilitate the placement of devices during diagnostic and interventional procedures.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

cigweld pty ltd - 60970 - fixed oxygen cylinder regulator - cylinder valve with integrated pressure regulator for use with medical gases

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

geoffrey chester - 60970 - fixed oxygen cylinder regulator - permanent installation on a cylinder for the administration of medical gases. fixed-regulator refillable cylinder. definition a container designed as a refillable cylinder with an integrated pressure regulator used to hold compressed medical oxygen under safe conditions at high pressures (e.g 50 - 200 bar). it is typically filled with oxygen when delivered from the gas supplier and includes a built-in pressure regulator and flowmeter that, when activated, releases the correct working pressure and flow rates. it is available in some cylinder sizes (capacity) and colour coded to denote oxygen content. the cylinder may be made of steel, aluminium or other ferrous and non-ferrous materials. oxygen is used as an essential life support gas, for anaesthesia and for therapeutic purposes.

캐나다 - 영어 - Health Canada

novo nordisk canada inc - liraglutide - solution - 6mg - liraglutide 6mg - incretin mimetics

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - tenofovir alafenamide fumarate, quantity: 11.2 mg; emtricitabine, quantity: 200 mg; elvitegravir, quantity: 150 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hyprolose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; microcrystalline cellulose; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - genvoya is indicated as a single tablet regimen for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25 kg who are either treatment?na?ve; or virologically suppressed (hiv-1 rna <50 copies/ml) on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see 5.1 pharmacodynamic properties, clinical trials). patients must not have a history of treatment failure or known mutations associated with resistance to the antiretroviral components of genvoya. genvoya is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide hiv-1 reverse transcriptase inhibitors.